Trial Profile
A Randomized, Double-blind, Placebo-Controlled, Dose Ranging, Parallel-Group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Plecanatide (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Acronyms IBS-C
- Sponsors Bausch Health Companies; Synergy Pharmaceuticals Inc
- 06 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 06 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 18 Jan 2021 Planned End Date changed from 31 Mar 2021 to 1 Dec 2022.